GGrantIndex
← Search

05 Tissue Biospecimen and Pathology Resource

$5,456P30FY2019CANIH

University Of Tx Md Anderson Can Ctr, Houston TX

Investigators

Linked publications, trials & patents

Trial NCT07407920Trial NCT07349641Trial NCT06651580Trial NCT05681026Trial NCT05223036Trial NCT05078866Trial NCT05057312Trial NCT05054296Trial NCT05044546Trial NCT05023967Trial NCT05011045Trial NCT04875728Trial NCT04870645Trial NCT04810091Trial NCT04751422Trial NCT04740164Trial NCT04668300Trial NCT04615013Trial NCT04505267Trial NCT04484909Trial NCT04483349Trial NCT04481204Trial NCT04474301Trial NCT04458610Trial NCT04447222Trial NCT04435691Trial NCT04430725Trial NCT04407247Trial NCT04373720Trial NCT04317781Trial NCT04311723Trial NCT04310826Trial NCT04310397Trial NCT04265430Trial NCT04257045Trial NCT04256941Trial NCT04239989Trial NCT04239976Trial NCT04239157Trial NCT04236882Trial NCT04228042Trial NCT04220827Trial NCT04220775Trial NCT04220008Trial NCT04219969Trial NCT04219904Trial NCT04216732Trial NCT04216563Trial NCT04216524Trial NCT04216472Trial NCT04215029Trial NCT04200534Trial NCT04199026Trial NCT04196972Trial NCT04189783Trial NCT04189770Trial NCT04189757Trial NCT04188418Trial NCT04188405Trial NCT04186884Trial NCT04186832Trial NCT04185337Trial NCT04181463Trial NCT04171622Trial NCT04171219Trial NCT04171037Trial NCT04169763Trial NCT04169737Trial NCT04169542Trial NCT04160052Trial NCT04151082Trial NCT04150939Trial NCT04140487Trial NCT04135326Trial NCT04134208Trial NCT04132843Trial NCT04132505Trial NCT04132440Trial NCT04129138Trial NCT04128748Trial NCT04128501Trial NCT04127721Trial NCT04125914Trial NCT04119037Trial NCT04106843Trial NCT04106245Trial NCT04090619Trial NCT04090567Trial NCT04087057Trial NCT04083378Trial NCT04082572Trial NCT04074746Trial NCT04066894Trial NCT04062305Trial NCT04062266Trial NCT04058964Trial NCT04054245Trial NCT04054167Trial NCT04054154Trial NCT04053517

Abstract

PROJECT SUMMARY: TISSUE BIOSPECIMEN AND PATHOLOGY RESOURCE (TBPR) The Tissue Biospecimen and Pathology Resource (TBPR) provides a flexible, sophisticated and well-functioning institutional biorepository for human tissue specimens in conjunction with an advanced research histology core facility that supports histopathologic characterization of human and animal tissue specimens. The biorepository Institutional Tissue Bank (ITB) and the Research Histology Facility (RHF) are 2 longstanding, mature, highly functional CCSG-supported shared resources that comprise the TBPR. The ITB is a CLIA-accredited facility that provides center members with access to human tissues, blood, and other fluids obtained from consenting patients under Institutional Review Board-approved protocols. The RHF provides routine and advanced cell- and tissue-based services to investigators. The TBPR supports the entire spectrum of research studies, including biomarker studies in clinical trials as well as basic and pre-clinical animal model research. During the last funding cycle, the ITB recruited board-certified pathologists' assistants to standardize and improve the quality of tissue collection throughout the institution. This effort continues to support new institutional initiatives and strategic alliances on clinical trials for the longitudinal collection of tissue and blood specimens for downstream molecular and immune profiling analyses and the associated implementation of new workflow processes. The TBPR director is Dr. Ignacio Wistuba, chair of Translational Molecular Pathology, and the co-directors are Dr. Stanley Hamilton, head of the Division of Pathology and Laboratory Medicine, and Dr. Dipen Maru, a professor in Translational Molecular Pathology. The TBPR provides key services, including: biospecimen collection, processing, distribution, and quality control; unique, specialized services, such as histochemical stains, immunohistochemistry (IHC), tissue microarray, laser-capture microdissection, in situ hybridization, and digital pathology that utilizes newly acquired, state-of-the-art equipment such as tissue microarrayers, IHC autostainers, and Aperio slide scanners; and new pathology consultation services. Over the last grant cycle, the ITB collected 637,042 specimens, and the RHF performed 1,069,932 procedures. MD Anderson has supported the TBPR with capital equipment funds that total $1,783,014 (ITB $385,387; RHF $1,397,627). Since the previous grant cycle, the ITB and RHL have supported 234 and 499 cancer center members, respectively, and usage was evenly distributed among all 16 CCSG programs. Peer review-funded research accounts for over 80% of total usage, and 32% ($614,243) is requested from the CCSG in grant Yr44. The TBPR facilitated the publication of 481 peer-reviewed papers, including 358 (74%) in journals with IF >5, 159 (33%) in journals with IF >10, and 70 (15%) in journals with IF >20. During the next funding cycle, the TBPR will continue to standardize, streamline, and optimize processes, thereby allowing the facilities to provide high-quality expedited services.

View original record on NIH RePORTER →